Philadelphia, PA – BioLabs announced the expansion and rebranding of its Philadelphia facility, now named BioLabs for Advanced Therapeutics.
Set to open its doors by the third quarter of 2025, the newly revamped 30,000-square-foot incubator is currently under construction at The Curtis and will cater to cutting-edge life science startups focusing on advanced therapeutics.
The expanded facility will feature a host of state-of-the-art amenities, including nine conference rooms, premium event space for life science gatherings, and specialized labs for microbiology, microscopy, and process development. BioLabs for Advanced Therapeutics aims to go beyond traditional coworking lab spaces, offering startups access to advanced equipment and educational programs designed to accelerate innovation in gene and cell therapies.
A major highlight of the expansion is the integration of Thermo Fisher Scientific’s east-coast flagship Advanced Therapies Collaboration Center (ATxCC), which will be embedded within the facility. This collaboration is expected to foster direct connections between BioLabs members and Thermo Fisher’s team of experts, allowing startups access to cutting-edge equipment and guidance for R&D and process development in advanced therapeutics.
“By combining BioLabs’ robust entrepreneurial ecosystem with Thermo Fisher’s industry expertise and state-of-the-art equipment, we are creating a unique environment for accelerating the development of life-saving therapies,” said a BioLabs spokesperson. A detailed announcement regarding the collaboration between BioLabs and Thermo Fisher will be released soon.
Key Benefits for Startups
BioLabs for Advanced Therapeutics offers a range of strategic advantages for startups in the advanced therapeutics space:
-
Integrated Biotech Ecosystem: Startups will gain access to a broad network of venture capital, industry leaders, and collaborators across BioLabs’ global network and the East Coast biotech community.
-
Accelerated Path to Patients: With specialized process development equipment, startups can develop therapies faster, more cost-effectively, and with reduced risks.
-
Direct Collaboration with Thermo Fisher Scientific: Startups will have the opportunity to work closely with Thermo Fisher scientists at the ATxCC, gaining expertise in gene therapy, cell therapy, and related fields.
-
Scalability and Growth: Located in the heart of Philadelphia, the Curtis offers seamless access to a cold-chain-enabled airport, public transportation, and other key biotech resources. Companies can scale from R&D to clinical trials within the same facility, with expansion opportunities into cGMP space in the building.
A Legacy of Innovation
Since its founding in 2009, BioLabs has fostered innovation by providing optimal environments for life science startups. With 16 locations across the U.S., Europe, and Japan, BioLabs has supported more than 550 biotech startups. In Philadelphia, BioLabs member companies have raised over $2 billion in funding since 2018, with seven alumni companies advancing to clinical trials.
Leasing Now Open
Leasing for BioLabs for Advanced Therapeutics begins this spring, with priority space reservations and special pricing for early members. Available lab spaces will range from single benches in shared open labs to private graduate suites with 23 benches. A limited number of spaces will be available immediately, with full availability expected by Q3 of 2025.
